Question
Do startup biotechs need products liability insurance?
Short answer
No - pre-commercial startup biotechs do not need products liability insurance until commercialization approaches. The relevant pre-commercial coverages are D&O (mandatory at term sheet), clinical trial liability (per active trial), cyber for clinical PHI and drug master file data, employment practices liability, fiduciary if plan assets exist, and IP infringement defense. Products liability activates at commercial launch, not at IND filing.
Why pre-commercial biotechs do not need products liability
Products liability insurance covers third-party bodily injury and property damage arising from a defective marketed product. Pre-commercial clinical-stage biotechs have no marketed product - the products liability policy has nothing to respond to.
During clinical development, subject injury arising from the trial intervention is covered by clinical trial liability (CTL), not products liability. CTL sits with the sponsor (or IND-holder) and responds to per-trial subject injury claims. The structural separation between CTL and products liability is by design - the two policies cover different exposure windows.
When does a biotech need to add products liability?
Products liability scope should be added 6-12 months before anticipated commercial launch. The typical trigger events: (1) BLA / NDA submission acceptance, (2) PDUFA action date within 12 months, (3) priority review designation, or (4) commercial launch preparation activities (commercial team hiring, manufacturing scale-up).
Adding products liability at the right time matters because the placement carriers active in pharmaceutical and biopharmaceutical products liability are a narrow specialty set - the placement should be sized to expected first-year commercial revenue and product class, not added in a rush at launch. Late additions or rushed placements typically produce sub-optimal terms.
What pre-commercial biotechs need instead
D&O insurance - mandatory once the company takes outside investor capital. Series A through Series C programs typically run $1M-$15M depending on stage, with step-ups at IPO/SPAC readiness ($25M-$100M+ Side A DIC + B + C).
Clinical trial liability - per active trial, sized by phase, sites, enrollment, geography, and indication. First-in-human Phase 1 $5M-$10M baseline; Phase 3 with EU sites $10M-$25M+.
Cyber liability - sized to drug master file (DMF) data, clinical PHI volume, and trade secret exposure. Pre-IND $1M-$3M; clinical-stage $3M-$10M; IPO-ready $5M-$15M.
Employment practices liability (EPLI) - once headcount exceeds 10-15.
Workers compensation - state-mandated.
Commercial general liability (CGL) - basic premises and ongoing-ops coverage.
IP infringement defense - for any biotech with platform IP licensed in from an academic institution.
Primary sources
Sources and references
This answer draws on the following regulatory, statutory, and standards-body sources. Coverage availability and program structure also depend on carrier appetite and underwriter discretion not captured by these sources.
- 21 CFR Part 312 - Investigational New Drug Applicationhttps://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-312
- FDA Drug Approvals and Databaseshttps://www.fda.gov/drugs/development-approval-process-drugs/drug-approvals-and-databases
Related practice areas
Insurance clauses in this area
Related questions
Have a more specific question?
A specialist will reach out by the end of the day.
Request a free coverage review